Mesa Laboratories financials
$130.98−1.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 | FY19 Mar 31 | FY18 Mar 31 | FY17 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.1M | $241.0M | $216.2M | $219.1M | $184.3M | $133.9M | $117.7M | $103.1M | $96.2M | $93.7M |
| Gross profit | $158.3M | $150.9M | $133.3M | $133.7M | $109.1M | $87.0M | $65.4M | $60.9M | $54.6M | $53.2M |
| Gross margin | 63.5% | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% | 55.5% | 59.1% | 56.8% | 56.8% |
| Operating income | $18.5M | $16.3M | -$272.1M | $3.3M | $4.7M | $12.4M | $7.9M | $9.8M | $2.2M | $16.3M |
| Net income | $6.7M | -$2.0M | -$254.2M | $930.0K | $1.9M | $3.3M | $1.8M | $7.5M | -$3.0M | $11.2M |
| Net margin | 2.7% | −0.8% | −117.6% | 0.4% | 1.0% | 2.4% | 1.5% | 7.3% | −3.1% | 11.9% |
| Diluted EPS | $1.21 | $-0.36 | $-47.20 | $0.17 | $0.35 | $0.64 | $0.41 | $1.86 | $-0.79 | $2.91 |
| EBITDA | $41.8M | $40.9M | $34.0M | $36.5M | $29.8M | $29.6M | $20.9M | $27.3M | $25.5M | $25.1M |
| Operating cash flow | $42.8M | $46.8M | $44.1M | $28.0M | $39.2M | $37.1M | $27.0M | $30.6M | $25.7M | $17.3M |
| Free cash flow | $39.6M | $42.6M | $41.6M | $23.4M | $34.8M | $35.1M | $25.5M | $29.3M | $22.9M | $5.7M |
| Diluted shares | 5.6M | 5.4M | 5.4M | 5.3M | 5.3M | 5.1M | 4.4M | 4.0M | 3.8M | 3.8M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.9M | $27.3M | $28.2M | $32.9M | $49.3M | $263.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $151.5M | $177.9M | $221.7M | $183.3M | $218.4M | $145.7M |
| Total assets | $427.7M | $433.3M | $446.8M | $661.8M | $707.4M | $601.5M |
| Total liabilities | $241.5M | $273.5M | $301.4M | $268.4M | $313.6M | $195.2M |
| Shareholders' equity | $186.2M | $159.8M | $145.4M | $393.5M | $393.8M | $406.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology